FAPI-Negative FDG-Avid Metastatic Relapse of Breast Cancer on PET/CT
Authors:
- 23 May 2023
- journal article
- editorial
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (8) , e380-e381
Abstract
A 69-year-old woman with breast cancer underwent 18F-FDG PET/CT because of the increased CA-15-3 level. 18F-FDG PET/CT showed multiple hypermetabolic lymph nodes (LNs) in the neck and mediastinum. The patient was also referred for 68Ga–fibroblast activation protein inhibitor (FAPI) 04 PET/CT for further evaluation. However, 18F-FDG–avid LNs were FAPI-negative on 68Ga-FAPI-04 PET/CT. Supraclavicular LN biopsy confirmed the metastasis of breast cancer. Recent reports have focused on the potential of FAPI PET imaging in breast cancer; however, this case highlights that false-negative 68Ga-FAPI-04-PET/CT findings should also be considered while evaluating metastatic spread.Keywords
This publication has 14 references indexed in Scilit:
- Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CTClinical Nuclear Medicine, 2022
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and ManagementFrontiers in Oncology, 2021
- Two Tumors, One TargetClinical Nuclear Medicine, 2021
- 68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Both [68Ga]Ga-FAPI and [18F]FDG PET/CT missed bone metastasis in a patient with breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CTAnnals of Nuclear Medicine, 2021
- Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04Clinical Nuclear Medicine, 2021
- Impact of 18F-FDG PET, PET/CT, and PET/MRI on Staging and Management as an Initial Staging Modality in Breast CancerClinical Nuclear Medicine, 2021
- Correlation of 18F-FDG PET/CT with pathological features and survival in primary breast cancerNuclear Medicine Communications, 2017